Thalidomide Plus Interferon Alfa in Treating Patients With Progressive Liver Cancer That Cannot be Surgically Removed
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Phase II trial to study the effectiveness of thalidomide plus interferon alfa in treating
patients who have progressive liver cancer that cannot be surgically removed. Thalidomide may
stop the growth of liver cancer by stopping blood flow to the tumor. Interferon alfa may
interfere with the growth of the cancer cells. Combining thalidomide and interferon alfa may
kill more tumor cells.